Levomilnacipran in the treatment of major depressive disorder : An analysis of efficacy and safety data from two phase III studies

被引：0
|
作者：
Greenberg, W. [1 ]
Commoll, C. [1 ]
Bose, A. [1 ]
Li, H. [1 ]
Ruth, A. [2 ]
Hussainzada, N. [3 ]
机构：
[1] Forest Res Inst, Jersey City, NJ USA
[2] Prescott Med, Commun Grp, Chicago, IL USA
[3] Forest Labs Inc, Washington, DC USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2012年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-14-014
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder
    Kamath, Jayesh
    DeMartinis, Nicholas
    Handratta, Venkatesh
    FUTURE NEUROLOGY, 2007, 2 (04) : 361 - 371
  • [22] Efficacy and clinical relevance of vilazodone in the treatment of major depressive disorder: a pooled analysis of phase III clinical trials
    Khan, A.
    Song, W.
    Edwards, J.
    Ruth, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S253 - S254
  • [23] Efficacy and clinical relevance of vilazodone in the treatment of major depressive disorder : A pooled analysis of phase III clinical trials
    Khan, A.
    Song, W.
    Ruth, A.
    Edwards, J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 186 - 187
  • [24] EFFICACY AND CLINICAL RELEVANCE OF VILAZODONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER: A POOLED ANALYSIS OF PHASE III CLINICAL TRIALS
    Culpepper, Larry
    Khan, Arif
    Ruth, Adam
    Edwards, John
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 : S71 - S72
  • [25] Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies
    Eriksson, Hans
    Weiller, Emmanuelle
    Weiss, Catherine
    Zhang, Peter
    Skuban, Aleksandar
    Thase, Michael E.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 102 - 102
  • [26] Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies
    Radecki, Daniel T.
    Robieson, Weining Z.
    Gopalkrishnan, Mallika
    Greenberg, Edward
    Aziz, Mohamed
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2024, 34 (05) : 241 - 250
  • [27] rTMS with a two-coil array: Safety and efficacy for treatment resistant major depressive disorder
    Carpenter, Linda L.
    Aaronson, Scott T.
    Clarke, Gregory N.
    Holtzheimer, Paul E.
    Johnson, Clark W.
    McDonald, William M.
    Stannard, Elizabeth L.
    Schneider, M. Bret
    BRAIN STIMULATION, 2017, 10 (05) : 926 - 933
  • [28] EFFICACY, SAFETY, AND TOLERABILITY CONSIDERATIONS IN THE NOVEL TREATMENT OF MAJOR DEPRESSIVE DISORDER
    Nierenberg, Andrew
    Kennedy, Sidney
    Lydiard, R. Bruce
    Rapaport, Mark Hyman
    CNS SPECTRUMS, 2009, 14 (03) : 1 - +
  • [29] Duloxetine: clinical efficacy, safety and tolerability in treatment of major depressive disorder
    Tarolla, E.
    Brugnoli, R.
    Pancheri, P.
    JOURNAL OF PSYCHOPATHOLOGY-GIORNALE DI PSICOPATOLOGIA, 2007, 13 (02): : 258 - 278
  • [30] EFFICACY AND SAFETY OF AGOMELATINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER: A PILOT STUDY
    Nukala, Srikrishna
    Komaram, Ravi Babu
    Palla, Jayasree
    Murthy, K. S. N.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2016, 7 (08): : 3517 - 3521
12345